170 related articles for article (PubMed ID: 29104462)
1. Association of
Nakamoto S; Imazeki F; Kanda T; Wu S; Nakamura M; Yasui S; Tawada A; Mikata R; Chiba T; Arai M; Yokosuka O; Shirasawa H
Int J Med Sci; 2017; 14(11):1088-1093. PubMed ID: 29104462
[TBL] [Abstract][Full Text] [Related]
2. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
3. A polymorphism in interferon L3 is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection.
Chang KC; Tseng PL; Wu YY; Hung HC; Huang CM; Lu SN; Wang JH; Lee CM; Chen CH; Tsai MC; Yen YH; Lin MT; Wu CK; Huang CC; Chen HH; Hu TH
Clin Gastroenterol Hepatol; 2015 May; 13(5):1017-24. PubMed ID: 25460552
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
5. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
[TBL] [Abstract][Full Text] [Related]
6. Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
Estrabaud E; Lapalus M; Broët P; Appourchaux K; De Muynck S; Lada O; Martinot-Peignoux M; Bièche I; Valla D; Bedossa P; Marcellin P; Vidaud M; Asselah T
J Virol; 2014 Jun; 88(11):6394-402. PubMed ID: 24672032
[TBL] [Abstract][Full Text] [Related]
7. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
Eslam M; Leung R; Romero-Gomez M; Mangia A; Irving WL; Sheridan D; Spengler U; Mollison L; Cheng W; Bugianesi E; McLeod D; Zaitoun AM; Attino V; Goeltz D; Nattermann J; Douglas M; Booth DR; George J; Ahlenstiel G
J Hepatol; 2014 Aug; 61(2):235-41. PubMed ID: 24768758
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Hashimoto Y; Ochi H; Abe H; Hayashida Y; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Nelson Hayes C; Ohishi W; Kubo M; Tsunoda T; Kamatani N; Nakamura Y; Chayama K
J Med Virol; 2011 Jun; 83(6):981-8. PubMed ID: 21503910
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
AlQaraawi AM; Sanai FM; Al-Husseini H; Albenmousa A; AlSheikh A; Ahmed LR; Hersi A; Al-Otaibi MM; Syed M; Ali SM; Al-hamoudi W; Alswat KA; Abdo AA
Dig Dis Sci; 2011 Apr; 56(4):1222-8. PubMed ID: 20931285
[TBL] [Abstract][Full Text] [Related]
10. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Hepatology; 2010 Aug; 52(2):421-9. PubMed ID: 20648473
[TBL] [Abstract][Full Text] [Related]
11. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
12. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
[TBL] [Abstract][Full Text] [Related]
14. Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.
Aoki Y; Sugiyama M; Murata K; Yoshio S; Kurosaki M; Hashimoto S; Yatsuhashi H; Nomura H; Kang JH; Takeda T; Naito S; Kimura T; Yamagiwa Y; Korenaga M; Imamura M; Masaki N; Izumi N; Kage M; Mizokami M; Kanto T
J Gastroenterol; 2015 Aug; 50(8):894-902. PubMed ID: 25501286
[TBL] [Abstract][Full Text] [Related]
15. Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.
Fabris P; Floreani A; Carlotto A; Baldo V; Bozzola L; Giordani MT; Negro F; Rassu M; Tramarin A; de Lalla F
Aliment Pharmacol Ther; 2005 May; 21(9):1173-8. PubMed ID: 15854181
[TBL] [Abstract][Full Text] [Related]
16. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
18. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
[TBL] [Abstract][Full Text] [Related]
20. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Kitabatake S; Murakami Y
Cytokine; 2013 Aug; 63(2):145-50. PubMed ID: 23673288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
